Share-based Payment Arrangement, Expense of CRISPR Therapeutics AG from 31 Dec 2014 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
CRISPR Therapeutics AG quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2014 to 30 Sep 2025.
  • CRISPR Therapeutics AG Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $16,604,000, a 23% decline year-over-year.
  • CRISPR Therapeutics AG Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $76,370,000, a 8% decline year-over-year.
  • CRISPR Therapeutics AG annual Share-based Payment Arrangement, Expense for 2024 was $86,567,000, a 6.8% increase from 2023.
  • CRISPR Therapeutics AG annual Share-based Payment Arrangement, Expense for 2023 was $81,028,000, a 17% decline from 2022.
  • CRISPR Therapeutics AG annual Share-based Payment Arrangement, Expense for 2022 was $97,947,000, a 4.3% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

CRISPR Therapeutics AG Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $76,370,000 $16,604,000 -$4,939,000 -23% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $81,309,000 $17,607,000 -$6,065,000 -26% 01 Apr 2025 30 Jun 2025 10-Q 04 Aug 2025 2025 Q2
Q1 2025 $87,374,000 $20,212,000 +$807,000 +4.2% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $86,567,000 $21,947,000 +$3,527,000 +19% 01 Oct 2024 31 Dec 2024 10-K 11 Feb 2025 2024 FY
Q3 2024 $83,040,000 $21,543,000 +$1,575,000 +7.9% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $81,465,000 $23,672,000 +$1,907,000 +8.8% 01 Apr 2024 30 Jun 2024 10-Q 04 Aug 2025 2025 Q2
Q1 2024 $79,558,000 $19,405,000 -$1,470,000 -7% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $81,028,000 $18,420,000 -$4,387,000 -19% 01 Oct 2023 31 Dec 2023 10-K 11 Feb 2025 2024 FY
Q3 2023 $85,415,000 $19,968,000 -$4,575,000 -19% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $89,990,000 $21,765,000 -$3,087,000 -12% 01 Apr 2023 30 Jun 2023 10-Q 05 Aug 2024 2024 Q2
Q1 2023 $93,077,000 $20,875,000 -$4,870,000 -19% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $97,947,000 $22,807,000 -$2,961,000 -11% 01 Oct 2022 31 Dec 2022 10-K 11 Feb 2025 2024 FY
Q3 2022 $100,908,000 $24,543,000 -$1,656,000 -6.3% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 $102,564,000 $24,852,000 -$3,479,000 -12% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $106,043,000 $25,745,000 +$3,653,000 +17% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $102,390,000 $25,768,000 +$6,838,000 +36% 01 Oct 2021 31 Dec 2021 10-K 21 Feb 2024 2023 FY
Q3 2021 $95,552,000 $26,199,000 +$8,959,000 +52% 01 Jul 2021 30 Sep 2021 10-Q 01 Nov 2022 2022 Q3
Q2 2021 $86,593,000 $28,331,000 +$12,634,000 +80% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $73,959,000 $22,092,000 +$7,941,000 +56% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $66,018,000 $18,930,000 +$7,073,000 +60% 01 Oct 2020 31 Dec 2020 10-K 21 Feb 2023 2022 FY
Q3 2020 $58,945,000 $17,240,000 +$2,467,000 +17% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $56,478,000 $15,697,000 +$3,499,000 +29% 01 Apr 2020 30 Jun 2020 10-Q 29 Jul 2021 2021 Q2
Q1 2020 $52,979,000 $14,151,000 +$3,455,000 +32% 01 Jan 2020 31 Mar 2020 10-Q 27 Apr 2021 2021 Q1
Q4 2019 $49,524,000 $11,857,000 -$2,186,000 -16% 01 Oct 2019 31 Dec 2019 10-K 15 Feb 2022 2021 FY
Q3 2019 $51,710,000 $14,773,000 +$5,706,000 +63% 01 Jul 2019 30 Sep 2019 10-Q 28 Oct 2020 2020 Q3
Q2 2019 $46,004,000 $12,198,000 +$2,721,000 +29% 01 Apr 2019 30 Jun 2019 10-Q 27 Jul 2020 2020 Q2
Q1 2019 $43,283,000 $10,696,000 +$4,023,000 +60% 01 Jan 2019 31 Mar 2019 10-Q 28 Apr 2020 2020 Q1
Q4 2018 $39,260,000 $14,043,000 +$6,611,000 +89% 01 Oct 2018 31 Dec 2018 10-K 16 Feb 2021 2020 FY
Q3 2018 $32,649,000 $9,067,000 +$3,840,000 +73% 01 Jul 2018 30 Sep 2018 10-Q 28 Oct 2019 2019 Q3
Q2 2018 $21,532,000 $9,477,000 +$5,246,000 +124% 01 Apr 2018 30 Jun 2018 10-Q 29 Jul 2019 2019 Q2
Q2 2018 $2,200,000 -$2,031,000 -48% 01 May 2018 31 May 2018 10-Q 07 Aug 2018 2018 Q2
Q1 2018 $23,563,000 $6,673,000 +$2,927,000 +78% 01 Jan 2018 31 Mar 2018 10-Q 29 Apr 2019 2019 Q1
Q4 2017 $20,636,000 $7,432,000 +$3,404,000 +85% 01 Oct 2017 31 Dec 2017 10-K 12 Feb 2020 2019 FY
Q3 2017 $17,232,000 $5,227,000 +$2,934,000 +128% 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2018 Q3
Q2 2017 $14,298,000 $4,231,000 +$730,000 +21% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $13,568,000 $3,746,000 +$2,724,000 +267% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q4 2016 $10,844,000 $4,028,000 01 Oct 2016 31 Dec 2016 10-K 25 Feb 2019 2018 FY
Q3 2016 $2,293,000 +$1,264,000 +123% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017 2017 Q3
Q2 2016 $3,501,000 01 Apr 2016 30 Jun 2016 10-Q 10 Aug 2017 2017 Q2
Q1 2016 $1,022,000 01 Jan 2016 31 Mar 2016 10-Q 11 May 2017 2017 Q1
Q3 2015 $1,029,000 01 Jul 2015 30 Sep 2015 10-Q 22 Nov 2016 2016 Q3

CRISPR Therapeutics AG Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $86,567,000 +$5,539,000 +6.8% 01 Jan 2024 31 Dec 2024 10-K 11 Feb 2025 2024 FY
2023 $81,028,000 -$16,919,000 -17% 01 Jan 2023 31 Dec 2023 10-K 11 Feb 2025 2024 FY
2022 $97,947,000 -$4,443,000 -4.3% 01 Jan 2022 31 Dec 2022 10-K 11 Feb 2025 2024 FY
2021 $102,390,000 +$36,372,000 +55% 01 Jan 2021 31 Dec 2021 10-K 21 Feb 2024 2023 FY
2020 $66,018,000 +$16,494,000 +33% 01 Jan 2020 31 Dec 2020 10-K 21 Feb 2023 2022 FY
2019 $49,524,000 +$10,264,000 +26% 01 Jan 2019 31 Dec 2019 10-K 15 Feb 2022 2021 FY
2018 $39,260,000 +$18,624,000 +90% 01 Jan 2018 31 Dec 2018 10-K 16 Feb 2021 2020 FY
2017 $20,636,000 +$9,792,000 +90% 01 Jan 2017 31 Dec 2017 10-K 12 Feb 2020 2019 FY
2016 $10,844,000 +$7,160,000 +194% 01 Jan 2016 31 Dec 2016 10-K 25 Feb 2019 2018 FY
2015 $3,684,000 +$2,989,000 +430% 01 Jan 2015 31 Dec 2015 10-K 08 Mar 2018 2017 FY
2014 $695,000 01 Jan 2014 31 Dec 2014 10-K 10 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.